COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 4 for:    H200
Previous Study | Return to List | Next Study

Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity (Botox + FES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00462449
Recruitment Status : Completed
First Posted : April 19, 2007
Results First Posted : June 20, 2014
Last Update Posted : June 20, 2014
Information provided by (Responsible Party):
Michael C. Munin, M.D., University of Pittsburgh

Brief Summary:

FES is a form of treatment with a device to aid movement in people who have had damage to their brain or spinal cord. Small electrical impulses are used to excite/stimulate the nerves that supply paralyzed muscles. This activates those muscles, enabling them to produce basic but useful movement. Self-adhesive patches (electrodes) are placed on the skin close to the nerve that supplies the muscle and are connected by wires to a stimulator that produces the impulses. In this way, FES is used to correct the muscle weakness that is caused by injury to the brain or spinal cord.

Repetitive task practice is an "activity-based" therapy program that has been shown to enhance the recovery of hand and arm functions after stroke. This therapy consists of a set of training activities that are designed by a qualified therapist specific to your functional abilities that are to be performed with the impaired hand. These activities are designed to stimulate functional improvement with repetitive practice.

Spasticity is a nervous system disorder where certain muscles are continuously contracted. Botox injections are commonly used to help to reduce spasticity in areas of the body with increased muscle tone. This research is designed to look at any additional benefit that may occur when Botox injections are combined with specific occupational therapy exercises and with a device that uses functional electrical stimulation (FES) to help improve muscle function after stroke.

Condition or disease Intervention/treatment Phase
Upper Extremity Spasticity Stroke Acquired Brain Injury Device: Functional Electrical Stimulation (FES) through the Ness H200 Not Applicable

Detailed Description:

This is a single-blinded, randomized controlled trial examining the effect of repetitive task practice (RTP) and functional electrical stimulation (FES) in individuals who receive routine clinical Botox ® injections for upper extremity spasticity. Botox® injections in combination with repetitive task practice (RTP) is used routinely to manage upper limb spasticity after stroke or acquired brain injury. RTP is an activity-based rehabilitation program that has been shown effective in promoting motor recovery (Wolf et al., 2002), but it requires a sufficient level of baseline motor function. Since FES enhances motor function, we hypothesize that an FES-assisted RTP intervention will provide greater improvement in hand function than RTP alone in patients receiving Botox ® injections.

The primary outcome will be upper extremity use during activities of daily living assessed observationally by the motor activities log (MAL-O). Secondary outcomes will be 1) dexterous hand function as measured by the action research arm test (ARAT); 2) client's perception of self-performance in activities of daily living assessed with the (MAL - Self Report); 3) global upper extremity impairment assessed by the Chedoke-McMaster Assessment (CMA); and 4) clinical spasticity assessed by the Modified Ashworth Scale (MAS).

The primary endpoint will be 6 weeks post-injection. Outcomes will also be assessed at a secondary endpoint, 12 weeks post-injection, to determine the persistence of treatment effects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Single Blind, Randomized Study to Determine the Safety and the Efficacy of Using Functional Electrical Stimulation (FES) and Repetitive Task Practice vs. Repetitive Task Practice Alone in Persons Receiving Botulinum Neurotoxin Type A Injections for Upper Extremity Spasticity
Study Start Date : November 2007
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox

Arm Intervention/treatment
No Intervention: 1
Individuals randomized into this group will only receive specialized therapy associated with this population.
Experimental: 2
In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
Device: Functional Electrical Stimulation (FES) through the Ness H200
Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
Other Name: NESS H200™ Product Specification

Primary Outcome Measures :
  1. Change From Baseline in Arm Function Based on Motor Activities Log (MAL-O) [ Time Frame: 12 weeks ]
    upper extremity function during activities of daily living based on observer ratings. Scale runs 0 (not used) to 5 (normal function). No subscales used.

Secondary Outcome Measures :
  1. Change From Baseline in Dexterous Hand Function as Measured by the Action Research Arm Test (ARAT) [ Time Frame: 12 weeks ]
    Dextrous hand function measurement. Scale ranges from 0 (no dextrous arm function) to 57 (normal function)

  2. Change From Baseline in Self-performance in Activities of Daily Living Assessed With the (MAL - Self Report) [ Time Frame: 12 weeks ]
    upper extremity function during activities of daily living as reported by the patient. Scale runs 0 (not used) to 5 (normal function). No subscales used.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Minimum 6 months post injury/insult with unilateral upper limb spasticity of the elbow, wrist and/or finger flexors.
  • Preinjection Modified Ashworth scores > 2 in at least one of the following areas: elbow, wrist, or finger flexors.
  • Subjects must meet criteria for CMA Hand Impairment Scale Stage 2 and be able to complete Task 3 (thumb to index finger) of the CMA Hand Impairment Scale Stage 3, or demonstrate 50% gross grasp to be included.
  • Botulinum toxin A (Botox®) stable patients (have received at least two prior doses of the agent with first dose occurring at least 6 months prior to study enrollment).
  • Able to answer reliably to yes/no questions.
  • Able to follow reliably 1-step instructions.
  • Written informed consent.
  • Females enrolled in this study who are of childbearing age will be required to use adequate measures of birth control for the entire study period. Those who do not agree will be excluded.

Exclusion Criteria:

  • Uncontrolled, clinically significant medical condition other than the condition under evaluation.
  • Severe, fixed joint contracture in the affected arm. Patients with mild contracture that does not significantly impact function will be included based upon the assessment of the PI.
  • Known allergy or sensitivity to any of the components in the study medication.
  • Females who are pregnant, breast-feeding, or planning a pregnancy during the study or who think that they may be pregnant at the start of the study, or females of childbearing potential who are unable or unwilling to use a reliable form of contraception during the study.
  • Concurrent participation in another investigational drug or device study or participation in the 30 days immediately prior to study enrollment.
  • Treatment with botulinum toxin of any serotype for any reason in less than 3 months prior to initial date of injection for the study.
  • Any medical condition that may put the subject at increased risk with exposure to botulinum toxin type A including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function.
  • Evidence of recent alcohol or drug abuse.
  • Infection or skin disorder at an anticipated injection and/or electrical stimulation sites.
  • Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
  • Use of aminoglycoside antibiotics, curare like agents, or other agents that might interfere with neuromuscular function.
  • Individuals with a cardiac pacemaker, a defibrillator, or baclofen pump.
  • Individuals with an unhealed or healing fracture or dislocation in the arm to be evaluated.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00462449

Layout table for location information
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Layout table for investigator information
Principal Investigator: Michael C. Munin, M.D. University of Pittsburgh
Rose DK, Winstein CJ, Tan SM, Azen SP, Chui HC. (2001). Comparison of upper extremity intervention strategies at six and nine months post-stroke. Neurol Rep 25: 130.
Winstein CJ, Rose DK, Chui HC et al. (2001) Recovery and rehabilitation of arm use after stroke. J Stroke Cerebrovasc Dis 10: 197.

Layout table for additonal information
Responsible Party: Michael C. Munin, M.D., Professor, University of Pittsburgh Identifier: NCT00462449    
Other Study ID Numbers: 0611012
First Posted: April 19, 2007    Key Record Dates
Results First Posted: June 20, 2014
Last Update Posted: June 20, 2014
Last Verified: June 2014
Keywords provided by Michael C. Munin, M.D., University of Pittsburgh:
Botulinum Toxin
Ness H200
Functional Electrical Stimulation
Repetitive Task Practice
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscle Spasticity
Brain Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations